Evidence map›Paper›PMID 41503128›Full record

ArticleJournal of surgical case reports2026

Neoantigen dendritic cell vaccination combined with conventional chemotherapy for a patient with advanced transverse colon cancer.

Hideya Onishi, Atsushi Higa, Mayu Tasaki, Yuki Inaoka, Aya Okuda, Yoshio Miki, Yasuaki Tsuchida, Hitoshi Hino, Masahiko Kawamoto, Shinya Ueda and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hideya OnishiOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Atsushi HigaOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Mayu TasakiOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Yuki InaokaOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Aya OkudaIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Yoshio MikiOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Yasuaki TsuchidaIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Hitoshi HinoNara City Hospital, 1-50-1 Higashikideracho, Nara, 630-8305, Japan.
Masahiko KawamotoIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Shinya UedaIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Nobuyuki TakaiIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Koshiro AndoIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Michiko TaniIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Nobuyuki TaniIseikai International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan.
Hisakazu YamagishiOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Yusuke NakamuraNational Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoasagi, Ibaraki, Osaka, 567-0085, Japan.
Kohji TaniOsaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, neoantigen dendritic cell (DC) vaccination has emerged as a promising personalized cancer immunotherapy based on genomic analysis. To further assess the clinical utility of this approach, additional data on the efficacy of neoantigen DC vaccination are needed. A 65-year-old male patient underwent curative surgical resection for pStage IIIB transverse colon cancer, followed by adjuvant DC vaccination combined with conventional chemotherapy for 6 months postoperatively. The neoantigen DC vaccination effectively reduced elevated carcinoembryonic antigen levels. Moreover, cytotoxic T lymphocytes (CTLs) isolated from the patient's peripheral blood demonstrated specific recognition of the neoantigen peptides. Our findings suggest that CTLs recognizing tumor-specific neoantigens may play an important role in immune surveillance against cancer recurrence. The patient remains alive and disease-free 16 months after surgery.

Indexed as

advanced colon cancerclass I antigencytotoxic T celldendritic cell vaccinationneoantigen

Identifiers

PMID41503128
PMCPMC12774506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.